Physician profile
Nabil Yazgi
NPI 1144337908
$9,650.24
in general payments reported to CMS, 2019-2025
55 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $1,102 · 2021: $1,538 · 2022: $1,626 · 2023: $1,317 · 2024: $1,612 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,430.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,085.87 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,009.46 | 2019-2025 | |
| Emd Serono, INC. | $692.35 | 2020-2024 | Mavenclad |
| Scilex Pharmaceuticals INC. | $584.27 | 2021-2025 | |
| Lilly USA, LLC | $496.82 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Allergan, INC. | $465.59 | 2019-2022 | |
| Pfizer INC. | $414.68 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $404.93 | 2019-2025 | Xtampza, Belbuca |
| Celgene Corporation | $351.59 | 2021-2025 | Zeposia |
| Ucb, INC. | $315.62 | 2019-2025 | Briviact, Nayzilam |
| Eisai INC. | $254.77 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $229.58 | 2019-2021 | |
| Biogen, INC. | $224.39 | 2019-2024 | Vumerity, Tysabri |
| Merck Sharp & Dohme LLC | $187.29 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $181.51 | 2020-2023 | Austedo Xr |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Yazgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.